155 related articles for article (PubMed ID: 33118660)
1. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol.
Waade RB; Solhaug V; Høiseth G
Br J Clin Pharmacol; 2021 May; 87(5):2228-2235. PubMed ID: 33118660
[TBL] [Abstract][Full Text] [Related]
2. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
4. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.
Jerling M; Dahl ML; Aberg-Wistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1996 Apr; 59(4):423-8. PubMed ID: 8612387
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
6. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
Beunk L; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Swen JJ; Touw D; van Westrhenen R; Deneer VHM; van der Weide J
Eur J Hum Genet; 2024 Mar; 32(3):278-285. PubMed ID: 37002327
[TBL] [Abstract][Full Text] [Related]
7. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients.
Tveito M; Smith RL; Molden E; Høiseth G
Eur J Clin Pharmacol; 2021 Feb; 77(2):215-221. PubMed ID: 33000414
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
[TBL] [Abstract][Full Text] [Related]
9. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
Tveito M; Molden E; Høiseth G; Correll CU; Smith RL
Eur J Clin Pharmacol; 2020 Jan; 76(1):41-49. PubMed ID: 31637453
[TBL] [Abstract][Full Text] [Related]
10. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
11. Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy.
Romskaug R; Wyller TB; Straand J; Kersten H; Molden E
Drugs Aging; 2020 Jun; 37(6):425-433. PubMed ID: 32346827
[TBL] [Abstract][Full Text] [Related]
12. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
Kringen MK; Bråten LS; Haslemo T; Molden E
J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
[TBL] [Abstract][Full Text] [Related]
13. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
Hendset M; Molden E; Knape M; Hermann M
Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Dahl ML
Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.
Hole K; Haslemo T; Molden E
Ther Drug Monit; 2023 Oct; 45(5):683-688. PubMed ID: 37012633
[TBL] [Abstract][Full Text] [Related]
17. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
Hendset M; Hermann M; Lunde H; Refsum H; Molden E
Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
[TBL] [Abstract][Full Text] [Related]
18. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
19. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol.
Linnet K; Wiborg O
Ther Drug Monit; 1996 Dec; 18(6):629-34. PubMed ID: 8946657
[TBL] [Abstract][Full Text] [Related]
20. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
